Uncover Model Selection Rationale for Diverse Oncology Models Balancing Predictability, Cost & Speed to Achieve Clinical Translatability
With the European oncology market increasingly focused on emerging modalities, highlighted by AbbVie’s recent licensing agreement with Ichnos Glenmark Innovation for their trispecific antibody, Boehringer Ingelheim’s partnership with Tempus to advance their cancer pipeline and the FDA’s new roadmap and the EMA encouraging drug developers to use non-animal tests in submissions, there has never been a more important year to stay up to date with the latest innovations in tumour modelling.
As the longest-standing forum from the world-renowned Tumour Models event series, the 14th Tumour Models Summit London returns to unite 130+ tumour modelling experts from pharma, biotech, and model providers from across the UK and Western Europe to soundboard recent model selection strategies with the goal of bridging the translational gap to the clinic.
I’m looking forward to raising awareness among scientists about the need for initiatives & roadmaps for alternatives to animal testing and to motivate them to deliver on these roadmaps as industry cannot develop all NAMs themselves.
Frederic Pipp, Global Animal Welfare Officer EMEA & APAC, Merck KGaA
I’m excited to gain and exchange knowledge on next generation preclinical models for cancer therapy development, from in silico, to in vitro to in vivo models. I am also interested to hear about the advantages and disadvantages of the different model platforms for specific therapeutic classes.
Sara Colombetti, Head of Global Department, Roche
I look forward to learning about the state-of-the-art in tumour models, as used by drug developers of many different modalities and network with colleagues around the world solving the same problems.
Stefanos Theoharis, Chief Executive Officer, OneChain Immunotherapeutics
Explore the Full Event Guide
- Free* to attend for biotech & pharma
- The longest-standing industry-focused meeting in the UK & western Europe dedicated to innovations & best practices in preclinical tumour modelling
- 18+ expert speakers delivering high-impact insights, practical experience & future-focused perspectives
- 16+ case studies on in vitro, complex in vitro, in vivo, in silico & more across diverse modalities & indications
- Exclusive networking & partnerships opportunities
Official Partners
Expertise Partners
Hosting Partner
Exhibition Partners
Innovation Partner
Attending Companies Include
Explore Related Events
Explore the Agenda
Hear the latest preclinical and translational data on tumour modelling, and gain first-hand insight into innovations during our packed agenda of case studies, interactive roundtables, poster competition and dedicated panel discussions.
Partner With Us
Position yourself as the partner of choice amongst leading model developers and solution providers to ensure your brand is at the heart of biopharma deals and collaborations.
Join Oncology Industry Experts
Be part of the hottest conversations with like-minded attendees spanning a range of oncology modalities and indications, and make critical connections during our dedicated networking sessions.